Search results for "Antiparkinson Agent"

showing 10 items of 24 documents

Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

2016

Levodopa (l-DOPA) is the most effective pharmacologic agent in Parkinson's disease and remains the "gold standard". Nevertheless, in long-term treatments, dyskinesias and motor complications can emerge. In this work, the combined use of l-DOPA methylester hydrochloride prodrug (LDME) with transbuccal drug delivery was supposed as a good alternative method to optimize the bioavailability of l-DOPA, to maintain constant plasma levels and to decrease the drug unwanted effects. The effects of environmental pH on buccal delivery of LDME were evaluated ex vivo. The increase of pH value from 5.8 to 6.2 implies an improvement of drug permeation. Since the pH increase causes the raising of hydrolyti…

DrugHydrochloridemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacologyAntiparkinson AgentsLevodopachemical stability03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineDrug StabilitySettore MED/28 - Malattie OdontostomatologicheProdrugsmedia_commonBuccal permeationMouthintellidrug deviceMouth MucosaParkinson DiseaseGeneral MedicineBuccal administrationPermeationProdrug021001 nanoscience & nanotechnologytransmucosal drug deliveryBioavailabilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryprodrug0210 nano-technology030217 neurology & neurosurgeryEx vivo
researchProduct

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

2002

Abstract The current concept of dyskinesia is that pulsatile stimulation of D-1 or D-2 receptors by l -DOPA or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. We now investigate the ability of two mixed D-1/D-2 agonists, namely pergolide (long-acting) and apomorphine (short-acting), to induce dyskinesia in drug-naive MPTP-lesioned primates, compared to l -DOPA. Adult common marmosets ( Callithrix jacchus ) were lesioned with MPTP (2 mg/kg/day sc for 5 days) and subsequently treated with equieffective antiparkinsonian doses of l -DOPA, apomorphine, or pergolide for 28 days. l -DOPA, apomorphine, …

Dyskinesia Drug-Inducedmedicine.medical_specialtyParkinson's diseaseL-DOPApergolideMotor ActivityapomorphineSeverity of Illness IndexDopamine agonistAntiparkinson AgentsLevodopaParkinson’s disease.Disability Evaluationchemistry.chemical_compoundParkinsonian DisordersDevelopmental NeuroscienceDopamineInternal medicineAnimalsMedicineMPTPPergolidemarmosetBehavior AnimalReceptors Dopamine D2business.industryReceptors Dopamine D1MPTPCallithrixmedicine.diseasenervous system diseasesApomorphineDisease Models AnimaldyskinesiaEndocrinologyNeurologychemistryDyskinesia1-Methyl-4-phenyl-1236-tetrahydropyridineDopamine receptorDopamine AgonistsSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drugExperimental Neurology
researchProduct

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study

2014

Background. The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). This post hoc analysis of DEEP study evaluates gender differences on WO and associated phenomena.Methods. Patients on dopaminergic treatment for ≥1 year were included in this multicenter observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as the use of the 19-item wearing-off questionnaire (WOQ-19); WO was defined for scores ≥2. Post hoc analyses were conducted to investigate gender difference for demographic and clinical features …

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyLevodopaParkinson's diseaseArticle SubjectCross-sectional studylcsh:MedicineDiseaseAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Medicine (all); Biochemistry Genetics and Molecular Biology (all); 2300lcsh:TechnologySeverity of Illness IndexBiochemistryGeneral Biochemistry Genetics and Molecular BiologyAntiparkinson AgentsLevodopaSex FactorsRisk FactorsInternal medicinePost-hoc analysisSeverity of illnessBIO/14 FarmacologiamedicineHumansProspective cohort studylcsh:ScienceGaitGeneral Environmental ScienceAgedAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Biochemistry Genetics and Molecular Biology (all); 2300; Medicine (all)2300business.industrylcsh:TMedicine (all)lcsh:RParkinson DiseaseGeneral Medicinemedicine.diseaseAkathisiaCross-Sectional StudiesDrug-InducedPhysical therapyObservational studylcsh:QFemalebusinessAkathisia Drug-InducedResearch Articlemedicine.drug
researchProduct

Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

2011

International audience; Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <6…

MaleParkinson's diseaseEpidemiologyConsensus Development Conferences as TopicParkinson's diseaseMESH: Antiparkinson AgentsDiseaseAntiparkinson AgentsLevodopa0302 clinical medicineMESH: Practice Guidelines as TopicEpidemiology030212 general & internal medicinePractice Patterns Physicians'Initial therapyMESH: Dopamine AgonistsMESH: AgedMESH: Levodopaeducation.field_of_studyMESH: Middle AgedConsensus conferenceParkinson DiseaseMiddle Aged3. Good healthNeurologyDopamine AgonistsPractice Guidelines as TopicMESH: Guideline AdherenceFemaleFranceGuideline Adherencemedicine.drugmedicine.medical_specialtyLevodopaPopulationGuidelines03 medical and health sciencesInternal medicineMedical practicemedicineHumansMESH: Physician's Practice PatternseducationAgedMESH: HumansMESH: Consensus Development Conferences as Topicbusiness.industrymedicine.diseaseMESH: MaleMESH: FrancePopulation based study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and GerontologybusinessMESH: FemaleMESH: Parkinson Disease030217 neurology & neurosurgeryParkinsonism &amp; Related Disorders
researchProduct

Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease

2008

Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which results in a loss of kinase domain on the PINK1 protein (D297fsX318). This mutation was identified in two brothers with early-onset Parkinson disease (EOPD) from a Sicilian consanguineous family. Of note, while one of the two patients developed mental deterioration and psychiatric problems, the other showed no cognitive decline. The present study supports the view that PINK1 is a pathogenic gene in some Italian families with EOPD and contributes to define the PINK1-associated phenotype. Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which r…

MaleParkinson's diseaseGenotypeParkinson's diseaseMolecular Sequence DataPINK1DiseaseBiologyAntiparkinson AgentsLevodopaExonmedicineHumansAmino Acid SequenceAge of OnsetCognitive declineGeneAgedGeneticsGenotype–phenotype correlationPINK1Parkinson DiseaseExonsFamilial formmedicine.diseasePhenotypePedigreeSettore BIO/18 - GeneticaPhenotypeNeurologyMutationMutation (genetic algorithm)Settore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyCognition DisordersProtein KinasesGene DeletionParkinsonism &amp; Related Disorders
researchProduct

Impaired reproduction of second but not millisecond time intervals in Parkinson's disease

2008

The basal ganglia have been associated with temporal processing in ranges of milliseconds and seconds. However, results from PD patient studies are elusive. Time perception in these patients has been tested with different approaches including repetitive movement tasks (i.e. finger tapping) and cognitive tasks (i.e. time reproduction), and both abnormal and normal performances have been reported for different time intervals. Furthermore, when PD patients were required to learn two target durations in the same session when they were off medication, they overestimated the short duration and underestimated the long duration in the seconds range. This pattern of temporal accuracy was described a…

MaleTime perception; Parkinson's disease; Basal ganglia; Dopamine; MemoryParkinson's diseaseDopamineNeuropsychological TestsAudiologyBehavioral neuroscienceAntiparkinson AgentsBehavioral NeuroscienceCognitionAttentionBRAINTomographyDepression; Humans; Tomography X-Ray Computed; Time Perception; Aged; Antiparkinson Agents; Memory Disorders; Cognition; Psychiatric Status Rating Scales; Parkinson Disease; Psychomotor Performance; Middle Aged; Neuropsychological Tests; Attention; Female; Male; Reaction TimeMillisecondDepressionParkinson DiseaseCognitionPsychiatric Status Rating ScaleMiddle AgedTime perceptionTIMEX-Ray ComputedNeuropsychology and Physiological PsychologyAntiparkinson AgentBasal gangliaNeuropsychological TestFemaleSettore MED/26 - NeurologiaPsychologyHumanMemory Disordermedicine.medical_specialtyElementary cognitive taskCognitive NeuroscienceExperimental and Cognitive PsychologyCognitive neuroscienceNOMemoryReaction TimemedicineHumansAgedPsychiatric Status Rating ScalesMemory DisordersSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaMemoriaTime PerceptionFinger tappingTomography X-Ray ComputedPARKINSONNeurosciencePsychomotor PerformanceNeuropsychologia
researchProduct

Motor intracortical inhibition in PD: L-DOPA modulation of high-frequency rTMS effects

2007

Dopaminergic drugs and deep brain stimulation restore cortical inhibition in Parkinson disease (PD) patients. High-frequency rTMS was also found to increase cortical inhibition in PD but its therapeutic effect is still controversial. Here we hypothesize that, if dopaminergic drugs reverse to normal cortical excitability in M1, the effect of high-frequency (hf)-rTMS in PD patients could depend on whether they are in a medicated or unmedicated state. The present study aims to explore the lasting effects of sub-threshold hf rTMS trains over M1 on cortical inhibition in patients with "on" and without "off" L-DOPA treatment. Fourteen PD patients were examined twice while "on" and "off" medicatio…

Malemedicine.medical_specialtyNeurologyDeep brain stimulationCORTICAL SILENT PERIODmedicine.medical_treatmentStimulationMotor ActivityInhibitory postsynaptic potentialPAIRED-PULSE INHIBITIONAntiparkinson AgentsLevodopaDegenerative diseaseEVOKED-POTENTIALSmedicineHumansCORTEX EXCITABILITYAgedAged 80 and overSUBTHALAMIC NUCLEUSPARKINSONS-DISEASE PATIENTSGeneral NeuroscienceDopaminergicMotor CortexNeural InhibitionParkinson DiseaseMiddle Agedmedicine.diseaseFACILITATIONCombined Modality TherapyTranscranial Magnetic StimulationTranscranial magnetic stimulationBRAIN-STIMULATIONmedicine.anatomical_structureSettore MED/26 - NeurologiaFemaleREPETITIVE TMSPsychologyNeuroscienceMotor cortexExperimental Brain Research
researchProduct

Death in the substantia nigra: a motor tragedy

2007

It is well known that the death of dopaminergic neurons of the substantia nigra pars compacta (SNc) is the pathological hallmark of Parkinson's disease (PD), the second most common and disabling condition in the expanding elderly population. Nevertheless, the intracellular cascade of events leading to dopamine cell death is still unknown and, consequently, treatment is largely symptomatic rather than preventive. Moreover, the mechanisms whereby nigral dopaminergic neurons may degenerate still remain controversial. Hitherto, several data have shown that the earlier cellular disturbances occurring in dopaminergic neurons include oxidative stress, excitotoxicity, inflammation, mitochondrial dy…

Motor NeuronsParkinson's diseasePars compactaGeneral NeuroscienceModels NeurologicalDopaminergicNeurogenesisParkinson DiseaseSubstantia nigraBiologymedicine.diseaseNeuroprotectionReceptors DopamineAntiparkinson AgentsSubstantia Nigranervous systemDopaminemedicineAnimalsHumansPharmacology (medical)Neurology (clinical)NeuroscienceNeuroinflammationmedicine.drugExpert Review of Neurotherapeutics
researchProduct

Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

2015

Dear Editor, We have read with interest comments by Solla et al. [1] regarding our Letter to the Editor published in NeurologicalSciences titled ‘‘Insidious onset of Pisa Syndrome afterrasagiline therapy in a patient with Parkinson’s Disease’’[2]. We thank the authors for their interest in our paper, but we think it is necessary to make some clarifications regarding the temporal relationship between the onset of Pisa Syndrome (PS) and rasagiline therapy. PS occurred in fact after and not before rasagiline treatment as stated by Solla et al. In particular, PS occurred after a time interval of 6–12 months and anyway after rasagiline was added to patient’s therapy. This long time interval is o…

Pediatricsmedicine.medical_specialtyParkinson's diseaseNeurologyParkinson's diseaseDermatologyAntiparkinson Agentschemistry.chemical_compoundDopaminemedicineHumansMonoamine Oxidase Type BDystoniaRasagilineAntiparkinsonian drugsbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasePsychiatry and Mental healthDystoniaPisa syndromechemistryAntiparkinson AgentsIndansFemaleNeurology (clinical)businessmedicine.drug
researchProduct